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Introduction
There is increasing evidence of activation of the innate im-
mune system in psychosis, although the precise role this acti-
vation plays in the etiology, degree and evolution of the 
structural/functional brain alterations remains unclear.1,2
Innate immunity is a nonspecific homeostatic response; how-
ever, if uncontrolled, it becomes harmful.3 The response is initi-
ated through the family of Toll-like receptors (TLRs), which are 
pattern recognition receptors that detect circulating pathogen-
associated molecular patterns (PAMPs) that are present in 
pathogens but not in mammalian cells. These patterns trigger a 
complex proinflammatory cascade that can regulate central ner-
vous system (CNS) homeostasis and even promote pathology.4 
Toll-like receptors are highly expressed in immune cells5 and in 
different types of CNS cells.6 This ubiquitous distribution sug-
gests that TLRs play other roles in non–pathogen- associated 
CNS diseases/injuries, presumably through recognizing a num-
ber of endogenous molecules released from damaged tissues 
(damage-associated molecular patterns [DAMPs]).7
The most studied member of the TLR family is TLR4, which 
mostly responds to lipopolysaccharide (LPS) from Gram- 
negative bacteria8 through its coreceptor: myeloid differentia-
tion protein-2.9 Through recruiting some other adaptor pro-
teins, such as the myeloid differentiation factor 88 (MyD88), 
TLR4 acquires specificity to intracellular signalling. After vari-
ous consecutive steps in the transduction pathway (i.e., acti-
vation of specific kinases, such as interleukin [IL]1 
 receptor-associated kinase 1 [IRAK1]), the prototypic inflam-
matory nuclear factor-κ B (NF-κB) is activated. This in turn 
triggers expression of the enzymes inducible nitric oxide syn-
thase (iNOS) and cyclooxygenase-2 (COX-2) and the activation 
of cytokines, such as IL-1β and IL-6. The activation of these 
proinflammatory mediators in the brain can produce an 
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Background: Alterations in the innate immune/inflammatory system may underlie the pathophysiology of schizophrenia, but we do not under-
stand the mechanisms involved. The main agents of innate immunity are the Toll-like receptors (TLRs), which detect molecular patterns associ-
ated with damage and pathogens. The TLR first reported was TLR4, and it is still the most studied one. Methods: We aimed to describe putative 
modifications to the TLR4 proinflammatory pathway using 2 different strategies in 2 cohorts of patients with schizophrenia and matched controls: 
1) quantification of protein and mRNA expression in postmortem prefrontal cortex samples from 30 patients with schizophrenia and 30 controls, 
and 2) identification of single nucleotide polymorphisms associated with the risk of schizophrenia using whole blood samples from 214 patients 
with schizophrenia and 216 controls. Results: We found evidence of alterations in the expression of the initial elements of the TLR4 signalling 
pathway (TLR4, Myeloid differentiation primary response gene 88 [MyD88] and nuclear factor-κ B [NF-κB]) in the PFC of patients with schizo-
phrenia. These alterations seem to depend on the presence/absence of antipsychotic treatment at death. Moreover, a polymorphism within the 
MyD88 gene was significantly associated with schizophrenia risk. Limitations: The use of 2 different approaches in 2 different cohorts, the lack 
of a complementary neuropsychiatric group, the possible confounding effects of antipsychotic treatment and suicide are the main limitations of 
our study. Conclusion: The evidence from this dual approach suggests there is an altered innate immune response in patients with chronic 
schizophrenia in which the TLR4 proinflammatory pathway could be affected. Improved understanding of the stimuli and mechanisms responsi-
ble for this response could lead to improved schizophrenia treatment and better control of the side effects of current antipsychotics.
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 accumulation of oxidative and nitrosative molecules, which 
can attack membrane phospholipids thereby causing cell dam-
age via lipid peroxidation.10 There are endogenous counter-
balancing mechanisms, such as activation of the anti- 
inflammatory nuclear receptor peroxisome proliferator- activated 
receptor γ (PPARγ)11,12 (Appendix 1, Fig. S1, available at jpn.ca).
Recently, a peripheral imbalance of these pro-/anti- 
inflammatory pathways was reported in patients with first-
episode psychosis (FEP) and in patients with chronic schizo-
phrenia with an acutely exacerbated condition.13–15 However, 
only a few studies report altered TLR expression or response 
to immune stimuli in patients with schizophrenia.16,17
A recent update reviews the randomized controlled trials 
of the efficacy of anti-inflammatory compounds in patients 
with schizophrenia.18 However, the effects of long-term anti-
psychotic treatment on the TLR4 signalling pathway and the 
putative therapeutic use of compounds capable of modula-
ting this pathway remains largely unexplored.
Interestingly, results from several genome-wide associa-
tion studies (GWAS) in patients with schizophrenia have re-
ported significant associations in chromosome regions that 
contain different genes related to the immune system and in-
flammation.19–22 Although no genetic association studies in-
clude TLR4 in patietns with schizophrenia, an increased fre-
quency of the TLR4 rs11536891 polymorphism was recently 
reported in patients with early-onset bipolar disorder com-
pared with controls.23
Several circumstances provide good reasons to study TLR4 
in schizophrenia populations specifically. First, some studies 
indicate that TLR4 may play a significant role in neurodevel-
opment and plasticity.24 Second, TLR4 could participate deci-
sively in the priming alterations of the fetomaternal immune 
system after infection/stress.25 Third, an altered microbiome 
and signs of intestinal inflammation, increased intestinal bar-
rier permeability and bacterial translocation are present in pa-
tients with schizophrenia.26 Finally, paliperidone regulates 
stress-induced activation of TLR4 in animal models.27
Taking into consideration all this background, in the present 
study we aimed to determine and report putative modifica-
tions of the TLR4 signalling pathway by using 2 different ap-
proaches: 1) quantification of protein and mRNA expression in 
postmortem prefrontal cortex (PFC) samples and 2) genetic as-
sociation analysis to identify single nucleotide polymorphisms 
(SNPs) associated with schizophrenia.
Methods
Postmortem human brain studies
Sample
Human brain samples were obtained from autopsies (Basque 
Institute of Legal Medicine, Bilbao, Spain) in compliance with 
research policies and ethical committees for postmortem brain 
studies. After a retrospective search for antemortem medical in-
formation, we obtained postmortem PFC brain samples from 
30 individuals who had a diagnosis of schizophrenia according 
to DSM-IV and from 30 controls matched for sex and age 
(± 4 yr) in a paired design. The criteria for selecting controls 
were absence of neuropsychiatric disorders and absence of 
drug abuse. We preferentially selected samples from controls 
with sudden and unexpected deaths in order to avoid possible 
confounding agonal influences. We screened blood from all 
sample donors to determine the presence of antipsychotics, 
other drugs and ethanol. According to the absence or presence 
of antipsychotic drugs in the toxicological screening, the schizo-
phrenia samples (and their matched contols) were divided into 
2 subgroups: antipsychotic-free (n = 17) and antipsychotic-
treated (n = 13). Characteristics of the definitive schizophrenia –
control pairs are shown in Appendix 1, Table S1. After comple-
tion of the assays, because the results of the 2 matched control 
subgroups did not differ for confounding factors (Appendix 1, 
Table S1), they were pooled for statistical analysis.
Specimens of PFC (Brodmann area [BA] 9) were dissected at 
autopsy (0.5–1 g tissue) following standard procedures.28 They 
were immediately stored at –80°C until assayed. Brain pH val-
ues were obtained at autopsy, and the RNA integrity number 
(RIN) was also assayed, as previously reported, as quality in-
dexes.29 The group averages for these parameters are shown in 
Appendix 1, Table S1.
Preparation of nuclear and cytosolic extracts from tissue 
samples
We used a modified procedure based on the method of 
Schreiber and colleagues30 (see Appendix 1 for details).
Western blot analysis
To determine the expression levels of TLR4, MyD88, iNOS and 
COX-2, PFC samples were homogenized by sonication in 
 phosphate-buffered saline (PBS) mixed with a protease inhibi-
tor cocktail (Complete®, Roche Farma) (pH = 7), followed by 
centrifugation at 12 000g for 10 min at 4º C. In the case of NF-κB 
and PPARγ, nuclear extracts were analyzed, whereas for the in-
hibitory subunit of NF-κB, IκBα, cytosolic extracts were used. 
Detailed information on primary and secondary antibodies can 
be found in Appendix 1.
Real-time polymerase chain reaction analysis
We prepared total cytoplasmic RNA from the PFC samples 
using TRIzol (Invitrogen). Aliquots were converted to 
complementary DNA (cDNA) using random hexamer 
primers. Quantitative changes in messenger RNA (mRNA) 
levels were estimated using real-time polymerase chain 
reaction. We calculated relative mRNA concentrations from 
the take-off point of the reactions using the software provided; 
glyceraldehyde 3-phosphate dehydrogenase (GADPH) and 
tubulin levels were used to normalize the data. The sequences 
of the primers can be found in Appendix 1.
Lipid peroxidation
Lipid peroxidation was measured using the thiobarbituric acid 
test for malondialdehyde (MDA) following the method de-
scribed by Das and Ratty31 (Appendix 1).
Nitrite levels
As the stable metabolites of nitric oxide, NO2- levels were 
meas ured using the Griess method (see Appendix 1 for  details).
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Statistical analysis
Data were analyzed using the GraphPad and InvivoStat pro-
grams. We processed each pair of samples for a case and 
matched control in parallel to control for experimental vari-
ance. Semiquantitative values for mRNA and protein were 
tested for a Gaussian distribution and compared using a 
 Student unpaired t test and 1-way analysis of variance 
(ANOVA), followed by the Fisher least significant difference 
(LSD) post hoc test. Correlations were analyzed to evaluate the 
influence of the postmortem delay, storage time and body mass 
index (BMI). When positive, we tested the results using analy-
sis of covariance (ANCOVA) with the corresponding factor as a 
covariate. The results are expressed as means ± standard errors 
of the mean. We considered results to be significant at p < 0.05.
Genetic association study
Participants
A total of 216 patients with schizophrenia diagnosed using the 
Structured Clinical Interview for DSM-IV (SCID-DSM-IV)32 
were recruited at the Psychiatric Service of the Hospital Clínic, 
Barcelona, Spain. We excluded 2 patients from the study 
 owing to technical genotyping problems, leaving 214 patients 
(139 men, 75 women, mean age 30.6 ± 11.3 yr) for our analysis. 
We selected 216 healthy controls matched for age and sex 
(140 men, 76 women, mean age 30.4 ± 11.2 yr) for the purpose 
of this study. A questionnaire was administered to each par-
ticipant in an interview to elicit demographic information, 
smoking habits and personal medical history. Moreover, the 
clinical information was checked against clinical records. Con-
trols were excluded if they reported a history of cancer or men-
tal disorder. All the participants were white and had previ-
ously participated in other genetic studies of schizophrenia 
risk.33 We obtained written informed consent and blood sam-
ples from each participant, and the Ethics Committee of the 
Hospital Clínic approved the study protocol.
Sample preparation
We collected blood samples from participants in ethylene-
diaminetetraacetic acid (EDTA; BD Vacutainer EDTA tubes, 
Becton Dickinson), and genomic DNA was extracted with the 
MagNA Pure LC DNA Isolation Kit III and an LC MagNA 
Pure system (Roche Diagnostics GmbH). We measured DNA 
concentration and quality spectrophotometrically using a 
NanoDrop 2000 (Thermo Fisher Scientific).
SNP selection and genotyping
We selected SNPs located in 9 genes known to be involved in 
the regulation of the TRL4 pathway, in accordance with data 
published in PubMed, Ensembl and the Genetic Association 
Database. Our aim was to find SNPs with functionality based 
on the consequence of the nucleotide change (e.g., missense), 
the location within the gene (e.g., regulatory region) or previ-
ously described associations (with protein levels, inflamma-
tory processes or schizophrenia risk and other mental disor-
ders; Table 1). We excluded SNPs with frequencies lower than 
5%. Some SNPs were rejected before genotyping owing to the 
assay rules. A total of 22 SNPs (Table 1) were genotyped 
Table 1: Twenty-two single nucleotide polymorphisms included in the genetic association study
Gene SNP Chr. position Gene position Major/minor alleles Minor allele frequency References*
LBP rs2232571 20:36974084 5’ upstream T/C 0.134 62
CD14 rs5744455 5:140013307 5’ upstream C/T 0.208 63
rs5744441 5:140016847 5’ upstream C/T 0.213 64
TLR4 rs4986790 9:120475302 Nonsynonymous A/G 0.056 61
rs4986791 9:120475602 Nonsynonymous C/T 0.053 61
rs11536889 9:120478131 3’UTR G/C 0.144 65
MyD88 rs4988453 3:38179254 5’ upstream C/A 0.042 66
rs4988457 3:38182136 Noncodifying exon C/G 0.043 66
rs7744 3:38184021 3’UTR A/G 0.153 50
IRAK4 rs4251545 12:44180295 Nonsynonymous G/A 0.110 67
IRAK1 rs3027898 X:153275890 3’ downstream A/C 0.199 68
NFKB1 rs28362491 4:103422155 5’ upstream ATTG /- 0.332 69
rs72696119 4:103422504 5’UTR C/G 0.329 70
rs2272676 4:103423326 Splicing region G/T 0.274 NR
rs230529 4:103457418 Intron region G/A 0.329 71
rs4699030 4:103503824 Intron region G/C 0.338 71
rs148268461 4:103534740 Splicing region - /A 0.053 NR
IL6 rs1800796 7:22766246 5’ upstream G/C 0.069 72
rs1800795 7:22766645 5’ upstream G/C 0.350 58
IL1B rs1143634 2:113590390 Synonymous C/T 0.227 58
rs1143627 2:113594387 5’UTR T/C 0.378 73
rs16944 2:113594867 5’ upstream G/A 0.375 58
NR = no reference; SNP = single nucleotide polymorphism; UTR = untranslated region.
*Includes 1 relevant reference on which the polymorphism selection was based. In cases of NR, the polymorphism was selected based just on 
its gene position. These references can be found in Appendix 1, available at jpn.ca.
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 using the MassArray assay with the Sequenom genotyping 
system at the Santiago de Compostela node of the Spanish 
National Genotyping Centre (CeGen). For quality control, 
10 samples were genotyped in duplicate for all the SNPs ana-
lyzed, with 100% concordance.
Statistical analysis
Sample size and statistical power calculations were per-
formed using Quanto 1.2 software. These calculations were 
based on allele frequencies in population genetics data from 
1000 genomes (Ensembl). Given the sample size and assum-
ing a 5% level of significance, we were able to detect odds ra-
tios of 1.9–2.3 with more than 80% statistical power when we 
analyzed SNPs with allele frequencies of 0.05–0.4.
We calculated means and standard deviations for continu-
ous variables. Univariate analysis (χ2 test for categorical vari-
ables and Student t test for continuous variables) was used to 
identify variables associated with the risk of schizophrenia 
 using SPSS statistics software version 20 (IBM). No differences 
in age or sex were detected. However, we observed significant 
differences in smoking habits (50.0% of patients v. 37.9% of 
controls, p = 0.024). To account for this, the statistical analysis 
was adjusted accordingly.
After quality control of the genotyping, all the SNPs were 
included in the statistical analysis, as all of them showed con-
sistent clustering and high genotyping rates (> 90% of sam-
ples), and none of them was out of Hardy–Weinberg equilib-
rium. To estimate the independent contribution of each SNP to 
schizophrenia risk, we assessed genotype frequencies by 
means of multivariate methods based on logistic regression 
analysis, with the analysis adjusted for variables significantly 
more common in patients with schizophrenia (smoking hab-
its). For this, we used the SNPassoc R package.34 The haplo-
type analysis was also performed using the SNPassoc R pack-
age. We performed SNP interaction analysis using the 
multifactor dimensionality reduction (MDR), as described 
elsewhere,35 and the MDR 2.0 software, available from the 
open-source MDR project (www.epistasis.org/software.html). 
Further information on the methods used in the SNP interac-
tion analysis can be found in Appendix 1.
To account for the multiple testing issue, we applied a 
 Bonferroni correction (0.05/number of SNPs analyzed) for 
the single SNP analysis (after Bonferroni correction, results 
were considered to be significant at p < 0.002) and permuta-
tion for the interaction analysis (the p value of the best model 
was corrected for multiple testing by 1000 permutation cycles 
using the MDR Permutation Testing Module 1.0).
Results
TLR4 pathway in postmortem human brain samples 
of  patients with schizophrenic and matched controls
TLR4 and MyD88 protein expression were higher in the post-
mortem PFC samples of patients with schizophrenia than 
matched controls (Fig. 1A and B). In addition, TLR4 displayed 
a positive correlation with storage time. The subsequent 
 ANCOVA, controlling for storage time, confirmed the ele-
vated TRL4 expression in patients with schizophrenia versus 
controls (p = 0.010). MyD88 mRNA levels did not differ be-
tween the groups (Fig. 1C). NF-κB expression in nuclear ex-
tracts was also higher in patients with schizophrenia than 
controls (Fig. 1D), but there were no changes in the protein 
levels of IκBα in cytosolic extracts (Fig. 1E); IL-1β and IL6 
mRNA levels were also the same for the control and schizo-
phrenia groups (Fig. 1F and G).
Expression of the iNOS and COX-2 enzymes was unaltered 
in patients with schizophrenia compared with controls 
(Fig.  1H and I). Similarly, PFC samples from patients with 
schizophrenia did not present a significant change in the 
lipid peroxidation index MDA (Fig. 1J) or NO2 levels 
(Fig. 1K) when compared with controls.
In order to study counterbalancing mechanisms, we evalu-
ated PPARγ expression. Western blot studies showed an in-
crease in nuclear PPARγ protein levels in the PFC of patients 
with schizophrenia compared with controls (Fig. 1L). TLR4 
pathway results were controlled for suicide, which was the 
cause of death of a large number of patients with schizophre-
nia. No influence was observed except for PPARγ protein lev-
els, where the difference between patients with schizophre-
nia and controls was attenuated (F1,57 = 3.09, p = 0.08).
Effect of antipsychotic treatment on TLR4 pathway
In order to determine the possible effect of antipsychotic treat-
ment on the TLR4 proinflammatory pathway, patients with 
schizophrenia were divided into 2 groups: antipsychotic-free 
and antipsychotic-treated at time of death. The treated patients 
presented higher levels of TLR4 and MyD88 protein expression 
than controls (Fig. 2A and B). No significant differences were 
found between antipsychotic-free patients and controls or 
 antipsychotic-treated patients in either parameter, although, es-
pecially for TLR4, the confidence interval for antipsychotic-free 
patients extended to the median of the treated patients. At the 
MyD88 mRNA expression level, treated patients presented 
higher levels than both control and antipsychotic-free patients, 
with no major differences between the latter 2 groups (Fig. 2C). 
This suggests that this effect could be not only medication- 
associated, but also genetically mediated.
Moreover, antipsychotic-free patients showed higher NF-κB 
expression than the control group (Fig. 2D). The remaining 
 parameters studied in blood did not differ between the 
 antipsychotic-free and treated patients at the time of death, ex-
cept for MDA levels, which appeared lower in antipsychotic-
free patients than controls and higher in antipsychotic-free 
 patients than in treated patients (Fig. 2J). Post hoc differences 
in MDA levels between controls and antipsychotic-free 
 patients (p = 0.020) were attenuated when we controlled for 
suicide (p = 0.06).
Genetic association study
The genotype frequencies of 3 SNPs differed between con-
trols and patients with schizophrenia (Table 2). While 4.2% of 
controls were homozygous for the minor frequency allele of 
MyD88 rs7744, no cases were homozygous for the same allele 
(p = 0.001). Regarding IL6 rs1800795, about 20% more 
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 controls than patients with schizophrenia were carriers of the 
minor frequency allele (p = 0.007). Moreover, differences in 
genotype frequencies of IL1B rs1143634 were also found: 
while only 3.7% of controls were homozygous for the minor 
frequency allele, 7.5% of patients with schizophrenia were 
homozygous for the same allele (p = 0.037). MyD88 rs7744 
was the only SNP that remained significantly associated with 
schizophrenia after Bonferroni correction. Haplotypes in 
MyD88 (rs4988453–rs4988457–rs7744) and IL6 (rs1800796–
rs1800795) were nominally associated. The frequency of the 
MyD88 CCG haplotype, containing the minor frequency al-
lele rs7744, was higher in controls than in patients with 
schizophrenia (18.5% v. 11.3%, p = 0.014). In the same way, 
the IL6 GC haplotype, containing the minor frequency allele 
rs1800795, was more common in controls than in patients 
with schizophrenia (18.5% v. 11.3%, p = 0.045). In both cases, 
the haplotype associations were no stronger than those found 
with the single polymorphisms alone. In fact, rs7744 and 
rs1800795 were responsible for the MyD88 and IL6 haplotype 
associations, respectively.
Fig. 1: Toll-like receptor-4 (TLR4) pathway in postmortem human brain samples from patients with schizophrenia (SZ) and matched controls. 
(A) TLR4 and (B) myeloid differentiation factor 88 (MyD88) protein levels. (C) Relative messenger RNA (mRNA) levels of MyD88. Protein levels of 
(D) nuclear factor κB (p65) and (E) inhibitory protein κBα. Messenger RNA levels of (F) interleukin (IL)1β and (G) IL6. Protein levels of (H) inducible 
 nitric oxide synthase (iNOS), (I) cyclooxygenase-2 (COX-2), (J) malondialdehyde (MDA) and (K) nitrite levels (NO2). (L) Protein levels of peroxi-
some proliferator-activated receptor γ (PPARγ) in the prefrontal cortex of patients with schizophrenia and matched controls. The densitometric data 
of the respective bands of interest are normalized with respect to β-actin/glyceraldehyde 3-phosphate dehydrogenase (lower band). *p < 0.05 com-
pared with controls; unpaired Student t test analysis. Data represent the means ± standard errors of the mean.
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The results of the exhaustive MDR analysis are given in 
Table 3. A 5-way model including the rs1800795 (IL6), 
rs7744 (MyD88), rs2272676 (NFKB1), rs1143627 (IL1B) and 
rs3027898 (IRAK1) variants performed best overall (train-
ing accuracy: 0.721; testing accuracy: 0.602) with a cross-
validation consistency of 100/100 (permutation testing p = 
0.010). The stepwise addition of the 5 variants increased the 
accuracy from 0.561 to 0.602. We constructed a multilocus 
attribute with the 5 SNPs. Carriers of the predisposing at-
tribute (69.9% of cases v. 30.1% of controls) were almost 
7  times more likely to develop schizophrenia than those 
without the attribute (odds ratio 6.9, 95% confidence inter-
val 4.4–10.6, p < 0.001). The predisposing genetic attribute 
we constructed correctly predicted 76.9% of cases (sensitiv-
ity), 67.3% of controls (specificity) and 72.1% of cases and 
controls (accuracy). Moreover, 69.9% of predicted cases 
were actual cases (precision).
Discussion
In the present study, evidence of the involvement of an al-
tered TLR4 pathway in patients with schizophrenia was 
found in both of the research approaches adopted. We con-
sidered it interesting to evaluate the TLR4 pathway at 
Fig. 2: Effect of antipsychotic treatment on Toll-like receptor-4 (TLR4) pathway in postmortem human brain samples of patients with schizo-
phrenia (SZ) and matched controls. (A) TLR4 and (B) myeloid differentiation factor 88 (MyD88) protein levels. (C) Relative messenger RNA 
(mRNA) levels of MyD88. Protein levels of (D) nuclear factor κB (p65) and (E) inhibitory protein κBα. Messenger RNA levels of (F) interleukin 
(IL)1β and (G) IL6. Protein levels of (H) inducible nitric oxide synthase (iNOS) and (I) cyclooxygenase-2 (COX-2), (J) malondialdehyde (MDA) 
and (K) nitrite levels (NO2). Protein levels of (L) peroxisome proliferator-activated receptor γ (PPARγ) in the prefrontal cortex of patients with 
schizophrenia free from or treated with antipsychotics and matched controls. *p < 0.05, **p < 0.01; 1-way analysis of variance followed by the 
Fisher least significant difference post hoc test. Data represent the means ± standard errors of the mean.
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 different stages, from genes to protein level, to strengthen the 
evidence of its role in the pathophysiology of schizophrenia.
In our search for polymorphisms, we tried to find possible 
etiological mechanisms, and through the postmortem study, 
we could check possible lifetime effects (including confound-
ing factors, such as age, BMI or medication) on the state and 
response of the innate immune system in a chronic clinical 
manifestation of the disease.
First, we found evidence of higher expression of TLR4 and 
MyD88 in the postmortem PFC of patients with schizophre-
nia. TLR4 upregulation in this brain area has also been dem-
onstrated in the PFC of alcoholic adolescents.36 In accordance 
with our results, NF-κB upregulation had previously been 
found in the postmortem PFC of patients with schizophrenia 
and in patients with other psychiatric diseases, such as de-
pression or autism.37–39 Recently, meta-analysis of gene coex-
pression networks in the postmortem PFC of patients with 
schizophrenia and controls found quantitative and clustering 
alterations in the module including immunity-related genes, 
such as TLR2, CD14, MYD88 and NFKBIA.40
Previous studies demonstrated a peripheral imbalance in 
the TLR4 signalling pathway in patients with schizophrenia. 
Enhanced TLR-dependent responses were observed, produ-
cing a massive release of IL6 or TNF-α.16 In addition, other 
authors found increased TLR4 expression in the monocytes 
of patients with schizophrenia.17 Interestingly, these mono-
cytes are less reactive to viral infection.
However, the origin of TLR4 activation in individuals with 
psychotic diseases remains unknown. Some nonexcluding 
mechanisms have been proposed. First, given the key role 
played by LPS in TLR4 stimulation, increased intestinal bar-
rier permeability and bacterial translocation have been re-
ported in patients with schizophrenia, as in those with major 
depression. Patients present an altered microbiome and, in 
some cases, intestinal inflammation.26 In addition, DAMPs 
are believed to be involved in the pathophysiology of psych-
otic disease,41 but their precise role remains unclear. Second, 
there is growing preclinical evidence that preperinatal infec-
tions can induce maternal immune activation and inflamma-
tory and oxidonitrosative stress that can lead to neurode-
velopmental damage and behavioural abnormalities in the 
progeny.25,42–45 In fact, activation of TLRs by infection has 
been reported to affect the fetomaternal immune response 
and cause behavioural abnormalities in descendants.44,45
Other possible sources of activation of the innate immune 
system have been recently suggested for major depressive dis-
order and could also be applicable to schizophrenia. These in-
clude psychosocial stressors, physical inactivity, obesity, 
smoking, poor dental care or overall hygiene and sleep depri-
vation.46 All these putative mechanisms of activation could ac-
tivate other TLRs; this is especially relevant considering that 
the degree and type of inflammatory response could vary de-
pending on the specific combinations of TLRs activated at the 
microglial level.47 This dynamic and heterogenic activation 
Table 2: Significant genotype associations
Group; no. (%)
SNP Schizophrenia Control OR (95% CI) p value*
rs7744 (MyD88)
AA+AG 214 (100.0) 207 (95.8) 1.00
GG 0 (0.0%) 9 (4.2) 0.00 (0.0–0.0) 0.001
rs1800795 (IL6)
GG 105 (49.1) 85 (39.4) 1.00
CG+CC 109 (50.9) 131 (60.6) 0.56 (0.5–0.9) 0.007
rs1143634 (IL1B)
CC+CT 198 (92.5) 208 (96.3) 1.00
TT 16 (7.5) 8 (3.7) 2.59 (1.0–6.5) 0.037
CI = confidence interval; OR = odds ratio; SNP = single nucleotide polymorphism.
*Logistic regression analysis adjusted for smoking habit. Results were considered to be significant 
at p < 0.002 after Bonferroni correction.
Table 3: Results of the multifactor dimension reduction analysis showing the best model of all possible 1- to 5-loci 
interactions and their outcome parameters
Model Training accuracy* Testing accuracy† CVC‡ p value§
rs1800795 0.561 0.561 100/100 0.46
rs2272676–rs3027898 0.586 0.420 63/100 > 0.99
rs1800795–rs2272676–rs3027898 0.616 0.421 61/100 0.39
rs1800795–rs7744–rs2272676–rs3027898 0.661 0.406 44/100 0.99
rs1800795–rs7744–rs2272676–rs1143627–rs3027898¶ 0.721 0.602 100/100 0.020
CVC = cross-validation consistency.
*Accuracy in the 100-fold training data set.
†Accuracy in the 100-fold testing data set.
‡100-fold CVC.
§p value of the best model corrected by 1000 permutations.
¶Odds ratio 6.9 (95% confidence interval 4.4–10.6), p < 0.001, sensitivity 76.9%, specificity 67.3%, accuracy 72.1%, precision 69.9%.
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further complicates the study and elucidation of the role of 
TLR4 in physiologic/pathophysiological CNS  conditions.
Efforts should be made to determine whether symptomatic 
onset of the disease occurs in a vulnerable brain (im muno-
logically primed months or years before symptoms manifest) 
or whether symptoms that will increase the deleterious 
 effects of inflammation or infection develop in genetically 
prone individuals.
It is worth discussing the differential results concerning the 
balance of pro-/anti-inflammatory pathways between the 
postmortem brain samples evaluated here and those previ-
ously reported at the systemic level in patients with FEPS and 
chronic schizophrenia.13–15 A significant increase in intracellu-
lar components of the NF-κB-dependent main proinflamma-
tory pathway (iNOS, COX-2 expression, and NO2 and MDA 
levels), along with a significant decrease in the anti-inflamma-
tory receptor PPARγ, have been reported in patients with FEPS 
and chronic schizophrenia. However, in our PFC samples, 
these proinflammatory parameters remained unaltered, and 
the expression of PPARγ increased. This switch in the pro-/
anti-inflammatory balance suggests that the degree and pro-
gression of the inflammatory process together with the nature 
of its autoregulatory mechanisms vary in the different stages 
of the illness or the different organic compartments studied. 
Although mRNA expression of IL-1β and IL-6 was not altered 
in the postmortem PFC samples from patients with schizo-
phrenia, a recent meta-analysis reported increased peripheral 
IL-1β and IL6 levels in acute psychosis that normalizes with 
antipsychotic treatment.48
In this particular clinical sample, the increased expression 
of TLR4/MyD88 seems to be predominantly influenced by 
the pharmacological treatment at the moment of death, 
which thus constitutes an important confounding factor. Al-
though the anti-inflammatory/antioxidant role of anti-
psychotics has previously been reported,49 their direct up-
stream effects on TLR4/MyD88 expression levels remained 
unexplored in human samples. Recent data in stress-based 
animal models show a potential regulatory role of paliperi-
done on TLR4 activation in the PFC.28
One of our most striking results is the higher content of 
MDA found in the PFC of patients with schizophrenia treated 
with antipsychotics compared with both antipsychotic-free 
 patients and controls. Our results agree with previous find-
ings that report a neurotoxic profile for high doses or chronic 
use of antipsychotics.50,51 Further studies are needed to 
 extend these findings to other brain areas or degrees of 
psych otic disease.
The results we obtained in the genetic association approach 
also suggest that the TLR4 signalling pathway is involved in 
the etiology of schizophrenia. Our results could indicate that 
individuals homozygous for the MyD88 rs7744 minor allele 
(GG) may have protection from schizophrenia. There are only 
a few studies of the presence or functional role of this poly-
morphism in human disorders. MyD88 rs7744 has been associ-
ated with autoimmune or inflammatory processes,52–54 but its 
biological function has not yet been identified. As it is located 
in the 3’ untranslated region (UTR) region, MyD88 rs7744 
could influence the stability of mRNA, thereby compromising 
normal protein levels. Moreover, it has been reported that an 
alternatively spliced form of MyD88 acts as a negative regula-
tor of TLR4, which leads to a reduced inflammatory re-
sponse.55 It may be that rs7744 was in linkage disequilibrium 
with another polymorphism that could influence this alterna-
tive splicing of the MyD88 gene. Either possibility would ex-
plain the reduced schizophrenia risk observed in individuals 
homozygous for the MyD88 rs7744 minor allele. Interestingly, 
MYD88 is located on chromosome 3p21.3-p22, a region previ-
ously linked with schizophrenia.56 More recently, several 
GWAS of schizophrenia have consistently reported positive 
signals in the 3p21 region, particularly in the ITIH family of 
genes,22,57,58 which codify for molecules that also seem to play 
an important role in inflammation.59
Our genetic results show that other genes related to the TLR4 
signalling pathway could also be involved in schizophrenia. 
Nominal associations were found for IL6 rs1800795 and IL1B 
rs1143634. Interestingly, both polymorphisms have previously 
been associated with the disease.60–62 Moreover, IL6 rs1800795, 
located in the promoter region, has been associated with in-
creased IL-6 blood levels61 and with reduced hippocampal vol-
ume in antipsychotic-naive patients with schizophrenia.63
We also propose a predictive genetic model for schizophre-
nia risk that includes the MyD88, IL6 and IL1B genes, as well 
as another 2 key genes in the intracellular signalling of the 
TLR4 pathway: NFKB1 and IRAK. The model identifies dif-
ferent genotype combinations of these 5 genes that allow the 
classification of patients with schizophrenia and healthy con-
trols with high sensitivity and specificity.
Our genetic results suggest that polymorphisms in genes 
related to the TLR4 pathway play a role in the pathophysiol-
ogy of schizophrenia, which would be in line with results 
from GWAS that report significant signals in regions that in-
clude different genes also related to the immune system and 
inflammation.19–22
Limitations
An important limitation of the present study was that the 2 ap-
proaches were applied in 2 different cohorts. No immune 
marker other than genetic ones could be examined in the 
 genetic cohort because no suitable samples were collected for 
such a purpose. Then, in order to detect a possible genetic ef-
fect, we did not consider it appropriate to increase the hetero-
geneity by considering the 2 cohorts together, particularly 
 taking into account the small increase of sample size that 
would have been achieved. In the future, when more post-
mortem samples have been collected, it will be interesting to 
assess the effect of the SNPs in that independent cohort.
At the moment, the significance of the higher expression of 
TLR4 and MyD88 in patients treated with antipsychotics 
compared with higher NF-κB in antipsychotic-free patients is 
difficult to interpret in a meaningful way. However, we must 
consider the fact that NF-κB is a master inflammatory mol-
ecule that could also be activated in mechanisms that are not 
directly related to the TLR4/MyD88 pathway.
In this vein, it is worth noting that the great majority of pa-
tients have experienced chronic treatment, even in the case of 
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the antipsychotic-free group. The presence of a statistically non-
significant trend toward elevated TLR4/MyD88 expression in 
antipsychotic-free patients could be interpreted in the context 
of a previous treatment period. With this type of postmortem 
brain samples, it is almost impossible to find medication-naive 
patients, but the toxicological screening that we performed 
guarantees no antipsychotic medication use in the month pre-
ceding death in antipsychotic-free patients.
Unfortunately, cytokine levels are studied only at the mRNA 
level, and there is a lack of concordance between the mRNA 
findings concerning cytokines and the genetic polymorphisms 
and haplotypes found. Further studies are required to check 
the functional consequences of these  polymorphisms.
The predictive capacity of our genetic model for schizophre-
nia, which includes SNPs in 5 TLR4 pathway genes, would 
need to be validated in independent populations. It is impor-
tant to highlight that MyD88 rs7744 and IL6 rs1800795 were 
the genetic variants that explained the highest percentage of 
the total entropy of the predictive model.
Finally, another limitation was the presence of several po-
tentially confounding factors in some of the individuals in-
cluded in the postmortem study, such as suicide as the cause 
of death.
Conclusion
The evidence from this dual approach suggests the existence 
of an altered innate immune response in patients with 
chronic schizophrenia, in which the TLR4 pathway could be 
one of those affected. Further research is needed to determine 
the state of the innate immune system in the different grades 
of psychotic disease (paying special attention to the potential 
confounding factor of antipsychotic treatment), the etiologic 
relevance of the polymorphisms found, and whether the 
pharmacological modulation of TLR4-dependent inflamma-
tory and oxidonitrosative stress is useful for the management 
of the symptomatology and chronic treatment of psychotic 
pathologies.
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